Orgone Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2020
- Revenue Growth 103.32%
- Profit Growth 90.23%
- Ebitda 102.98%
- Net Worth -161.82%
- Total Assets -77.46%
About Orgone Pharmaceuticals
Orgone Pharmaceuticals Private Limited (OPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 July 2016 (Eight years and seven months 8 days old ). Its registered office is in Patna, Bihar, India.
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Avinash Kumar, Niharika Jaiswal, and Jyoti Srivastava serve as directors at the Company.
Company Details
-
Location
Patna, Bihar, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74995BR2016PTC031932
-
Company No.
031932
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Jul 2016
-
Date of AGM
31 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Orgone Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Avinash Kumar
|
Director | 04-Jul-2016 | Current |
|
Niharika Jaiswal
|
Director | 04-Jul-2016 | Current |
|
Jyoti Srivastava
|
Director | 04-Jul-2016 | Current |
Financial Performance of Orgone Pharmaceuticals.
Orgone Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 103.32% increase. The company also saw a substantial improvement in profitability, with a 90.23% increase in profit. The company's net worth observed a substantial decline by a decrease of 161.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Orgone Pharmaceuticals?
In 2017, Orgone Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Equinox Pharmaceuticals Private LimitedAvinash Kumar is a mutual person
-
Vr Medical And Pharmaceuticals Private Limited
Jyoti Srivastava is a mutual person
-
Ubl Remedies Private Limited
Jyoti Srivastava is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Orgone Pharmaceuticals?
Unlock and access historical data on people associated with Orgone Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Orgone Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Orgone Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.